427 related articles for article (PubMed ID: 13129824)
1. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment.
Alexiou C; Jurgons R; Schmid RJ; Bergemann C; Henke J; Erhardt W; Huenges E; Parak F
J Drug Target; 2003 Apr; 11(3):139-49. PubMed ID: 13129824
[TBL] [Abstract][Full Text] [Related]
2. Locoregional cancer treatment with magnetic drug targeting.
Alexiou C; Arnold W; Klein RJ; Parak FG; Hulin P; Bergemann C; Erhardt W; Wagenpfeil S; Lübbe AS
Cancer Res; 2000 Dec; 60(23):6641-8. PubMed ID: 11118047
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.
Krukemeyer MG; Krenn V; Jakobs M; Wagner W
J Surg Res; 2012 Jun; 175(1):35-43. PubMed ID: 21470623
[TBL] [Abstract][Full Text] [Related]
4. [Magnetic Drug Targeting--a new approach in locoregional tumor therapy with chemotherapeutic agents. Experimental animal studies].
Alexiou C; Jurgons R; Schmid R; Erhardt W; Parak F; Bergemann C; Iro H
HNO; 2005 Jul; 53(7):618-22. PubMed ID: 15549214
[TBL] [Abstract][Full Text] [Related]
5. Real-time cell analysis of human cancer cell lines after chemotherapy with functionalized magnetic nanoparticles.
Dürr S; Lyer S; Mann J; Janko C; Tietze R; Schreiber E; Herrmann M; Alexiou C
Anticancer Res; 2012 May; 32(5):1983-9. PubMed ID: 22593476
[TBL] [Abstract][Full Text] [Related]
6. Visualisation of tumour regression after local chemotherapy with magnetic nanoparticles - a pilot study.
Lyer S; Tietze R; Jurgons R; Struffert T; Engelhorn T; Schreiber E; Dörfler A; Alexiou C
Anticancer Res; 2010 May; 30(5):1553-7. PubMed ID: 20592340
[TBL] [Abstract][Full Text] [Related]
7. Magnetorelaxometric quantification of magnetic nanoparticles in an artery model after ex vivo magnetic drug targeting.
Richter H; Wiekhorst F; Schwarz K; Lyer S; Tietze R; Alexiou Ch; Trahms L
Phys Med Biol; 2009 Sep; 54(18):N417-24. PubMed ID: 19700820
[TBL] [Abstract][Full Text] [Related]
8. Magnetic targeting after femoral artery administration and biocompatibility assessment of superparamagnetic iron oxide nanoparticles.
Ma HL; Qi XR; Ding WX; Maitani Y; Nagai T
J Biomed Mater Res A; 2008 Mar; 84(3):598-606. PubMed ID: 17618488
[TBL] [Abstract][Full Text] [Related]
9. Preparation of carboplatin-Fe@C-loaded chitosan nanoparticles and study on hyperthermia combined with pharmacotherapy for liver cancer.
Li FR; Yan WH; Guo YH; Qi H; Zhou HX
Int J Hyperthermia; 2009 Aug; 25(5):383-91. PubMed ID: 19391033
[TBL] [Abstract][Full Text] [Related]
10. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
[TBL] [Abstract][Full Text] [Related]
11. Clinical applications of magnetic drug targeting.
Lübbe AS; Alexiou C; Bergemann C
J Surg Res; 2001 Feb; 95(2):200-6. PubMed ID: 11162046
[TBL] [Abstract][Full Text] [Related]
12. Targeting cancer cells: magnetic nanoparticles as drug carriers.
Alexiou C; Schmid RJ; Jurgons R; Kremer M; Wanner G; Bergemann C; Huenges E; Nawroth T; Arnold W; Parak FG
Eur Biophys J; 2006 May; 35(5):446-50. PubMed ID: 16447039
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells.
Kohler N; Sun C; Wang J; Zhang M
Langmuir; 2005 Sep; 21(19):8858-64. PubMed ID: 16142971
[TBL] [Abstract][Full Text] [Related]
14. [Targeting technology utilizing magnetic microparticulate system for cancer therapy].
Morimoto Y; Natsume H
Nihon Rinsho; 1998 Mar; 56(3):649-56. PubMed ID: 9549351
[TBL] [Abstract][Full Text] [Related]
15. Iron oxide nanoparticles for sustained delivery of anticancer agents.
Jain TK; Morales MA; Sahoo SK; Leslie-Pelecky DL; Labhasetwar V
Mol Pharm; 2005; 2(3):194-205. PubMed ID: 15934780
[TBL] [Abstract][Full Text] [Related]
16. Quantification of magnetic nanoparticles by magnetorelaxometry and comparison to histology after magnetic drug targeting.
Wiekhorst F; Seliger C; Jurgons R; Steinhoff U; Eberbeck D; Trahms L; Alexiou C
J Nanosci Nanotechnol; 2006; 6(9-10):3222-5. PubMed ID: 17048540
[TBL] [Abstract][Full Text] [Related]
17. A preliminary study on MeO-PEG-PLGA-PEG-OMe nanoparticles as intravenous carriers.
Duan Y; Xu J; Lin Y; Yu H; Gong T; Li Y; Zhang Z
J Biomed Mater Res A; 2008 Nov; 87(2):515-23. PubMed ID: 18186066
[TBL] [Abstract][Full Text] [Related]
18. Folic acid-Pluronic F127 magnetic nanoparticle clusters for combined targeting, diagnosis, and therapy applications.
Lin JJ; Chen JS; Huang SJ; Ko JH; Wang YM; Chen TL; Wang LF
Biomaterials; 2009 Oct; 30(28):5114-24. PubMed ID: 19560199
[TBL] [Abstract][Full Text] [Related]
19. Delivery of superparamagnetic nanoparticles for local chemotherapy after intraarterial infusion and magnetic drug targeting.
Alexiou C; Jurgons R; Seliger C; Brunke O; Iro H; Odenbach S
Anticancer Res; 2007; 27(4A):2019-22. PubMed ID: 17649815
[TBL] [Abstract][Full Text] [Related]
20. Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets - sarcoma treatment in progress.
Krukemeyer MG; Krenn V; Jakobs M; Wagner W
J Drug Target; 2012 Feb; 20(2):185-93. PubMed ID: 22044194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
